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Abstract
Background: The relationship between ERCC2 polymorphisms and the risk of radiotoxicity remains inconclusive.
The aim of our study is to systematically evaluate the association between ERCC2 polymorphisms and the risk of
radiotoxicity.
Methods: Publications were identified through a search of the PubMed and Web of Science databases up to
August 15, 2015. The pooled odds ratios (ORs) with corresponding 95 % confidence intervals (CIs) were calculated to
evaluate the association between ERCC2 polymorphisms and radiotoxicity. Trial sequential analysis (TSA) and power
calculation were performed to evaluate the type 1 and type 2 errors.
Results: Eleven studies involving 2584 patients were ultimately included in this meta-analysis. Conventional meta-analysis
identified a significant association between ERCC2 rs13181 polymorphism and radiotoxicity (OR = 0.71, 95 % CI: 0.55-0.93,
P = 0.01), but this association failed to get the confirmation of TSA.
Conclusions: The minor allele of rs13181 polymorphism may confer a protect effect against radiotoxicity. To confirm
this correlation at the level of OR = 0.71, an overall information size of approximate 2800 patients were needed.
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Introduction
Radiotherapy is commonly used in cancer treatment. At
least half of cancer patients will require radiotherapy with
either curative or palliative intent [1]. However, the adverse
effect induced by radiotherapy restricts this modality from
playing a larger role in the multidisciplinary therapy of
cancer. It has been widely noticed that patients were not
homogeneous in the reaction of normal tissue following
radiotherapy [2, 3]. The standard radiotherapy schedule
was recommended treating the cancer patients as a whole,
which was actually miscellaneous with patients of different
radio-sensitivity. So the radio-resistive patients who can
bear more doses of radiotherapy were confined in the
protocol of standard radiotherapy with the radio-sensitive
patients who may even fail the cost-benefit evaluation of
receiving radiotherapy. Consequently, the likelihood of a
cure was to some extent reduced for some patients. On
the other hand, for some others, the standard radiotherapy
was still too harmful to the balance between the thera-
peutic effect and the normal tissue injury. It is believed
that a genetic basis plays an important role in this hetero-
geneous response to radiation [4, 5].
‘Radiogenomics’ is the study of genetic variation as-
sociated with response to radiotherapy, with a main
purpose of establishing single nucleotide polymorph-
ism (SNP) based risk models that can stratify patients
according to radio-sensitivity [6, 7]. In the last decade,
candidate gene association studies have identified sev-
eral potential predictors for radio-sensitivity. Due to
the insufficient sample size of these studies and rela-
tively small effects conferred by relevant SNPs, it
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makes much sense to systematically synthesize the pre-
vious evidence. Recently, we have reviewed several
SNPs in radiogenomics, including ATM [8], XRCC3 [9]
and XRCC1. The aim of the present meta-analysis is to
evaluate the effect of excision repair cross-complementing
2 (ERCC2, also known as XPD, xeroderma pigmentosum
group D ) polymorphisms on radiotoxicity.
ERCC2 protein is an essential component of the general
transcription factor TFIIH complex that plays a key role
in nucleotide excision repair (NER) and basal transcription
[10–14]. Besides a 5’-3’ helicase activity, ERCC2 also plays
a bridging function within the TFIIH complex [13, 15].
Mutations in ERCC2/XPD have been associated with
three hereditary diseases, namely Xeroderma pigmento-
sum (XP), Cockayne Syndrome and Trichothyodystro-
phy (TTD) [10, 13, 16]. However, in vitro studies failed
to relate the polymorphisms of ERCC2 to DNA repair
capacity [13, 17–19].
Materials and methods
Search strategy and inclusion criteria
Two investigators independently searched the PubMed,
and Web of Science databases through a comprehensive
search strategy including the terms “SNP”, “ERCC2/
XPD”, “radiotherapy” and “toxicity” (see Additional file 1
for the specific strategy). The searching result was last
updated on August 15, 2015. Studies satisfying the fol-
lowing criteria were eligible for inclusion: (1) case–con-
trol study or cohort study; (2) evaluated the effect of
ERCC2 polymorphisms on radiotoxicity; (3) adequate in-
formation provided to calculate the odds ratio (OR) and
the corresponding 95 % confidence interval (CI). There
were no limitations on the language of publication. To
avoid exaggerating the representation of certain study, the
effect of each study should be cumulated only one time in
the synthetical result. If a single study evaluated multiple
toxicities, we included the most common toxicity to re-
duce the potential heterogeneity between studies.
Data extraction
Two investigators independently extracted data from
each included study using a standard data collection
form. The following information was extracted: first au-
thor’s surname, year of publication, country of origin,
ethnicity, cancer type, radiotoxicity, assessment criteria,
and ORs with the corresponding 95 % CI for the associ-
ation between ERCC2 polymorphisms and radiotoxicity.
Study authors were contacted when the data provided
was insufficient. Disagreements were resolved by discus-
sion among all investigators.
Statistical methods
The pooled OR and 95 % CI were calculated to assess the
strength of the association between ERCC2 polymorphisms
and the risk of radiotoxicity. Meta-analysis was first per-
formed on each included polymorphism under 3 genetic
comparison models: dominant model (mutant homozy-
gote/heterozygote vs. wild type), recessive model (mutant
homozygote vs. wild type/heterozygote) and allelic model
(minor allele vs. common allele). Subsequently, subgroup
analyses were conducted by adverse effect. The heterogen-
eity between studies was assessed with the chi-squared
based Q-test and I2 statistics [20, 21]. When the chi-
squared P was <0.10 or the I2 statistic was ≥50 %, the het-
erogeneity was considered statistically significant, and a
random-effects model (DerSimonian-Laird method) was
applied [22]; otherwise, a fixed-effects model (Mantel-
Haenszel method) was accepted [23]. Sensitivity analysis
was performed to evaluate the stability and reliability of the
pooled results by excluding each study individually and
reanalyzing the remaining studies. Publication bias was
evaluated via Begg’s funnel plot and Egger’s test [24, 25]. If
publication bias existed, the “trim and fill” method was ap-
plied to estimate the number of missing studies and to ad-
just the pooled result [26]. Statistical power calculation was
performed to evaluate the potential type 2 errors for the
primary and subgroup analyses. A two-sided P <0.05 was
considered significant for all the analyses except the het-
erogeneity tests. Meta-analyses were performed using Stata
(Version 14.0, StataCorp LP, College Station, TX, USA).
Trial sequential analysis (TSA) was performed for the
analyses involving more than six studies. A two sided
α = 0.05, β = 0.2 and a relative risk reduction (RRR) of 10 %
were used. A required information size was estimated with
the adjustment by diversity (D2) between studies [27, 28].
An α-spending boundary and a futility boundary were
constructed accordingly. The cumulative z-curve was pro-
duced by plotting a series of z-values of cumulative meta-
analyses [29]. If the accrued number of included patients
surpassed the required information size, it means that a
sufficient level of evidence has been reached. If the curve
crossed the α-spending boundary, it was considered that
the conclusion of significant association was confirmed.
When the z-curve crossed the futility boundary, the
conclusion of indiscrimination between two groups was
accepted under the given conditions [30]. TSA was per-




A flow diagram summarizing the literature review process
and reasons for exclusion is presented in Fig. 1. A total of
11 studies involving 502 cases and 2082 controls were
eventually included in this meta-analysis. The baseline
characteristics of the included studies are presented in
Table 1. The studies were published from 2005 to 2013,
and the sample sizes ranged from 60 to 698. Three SNPs
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of ERCC2 were involved in the present meta-analysis:
ERCC2 Lys751Gln (rs13181) (nine studies), Asp312Asn
(rs1799793) (five studies) and Asp711 (rs1052555) (two
studies). Cancer categories included breast cancer (six
studies), lung cancer (one study), esophageal cancer (one
study), prostatic carcinoma (one study), bladder cancer
(one study) and rectal cancer (one study).
Meta-analysis results
Significant associations between rs13181 and risk of radiotoxi-
city were identified in dominant model (OR= 0.71, 95 % CI:
0.55-0.93, P= 0.01) and allelic model (OR= 0.78, 95 % CI:
0.64-0.97, P = 0.02) by conventional meta-analysis (Fig. 2,
Table 2). TSA suggested that more than half (1486/2804)
of the required information size has been accrued (Fig. 3).
The cumulative z-curve (dominant model) has transcended
the conventional significance boundary, which was in
accordance with the result of conventional meta-analysis.
No trial sequential monitoring boundary was further
crossed, leaving the meta-analysis inconclusive of a 10 %
relative risk reduction. For rs1799793 and rs1052555 poly-
morphisms, no significant association was identified.
Subgroup analyses were performed only under domin-
ant model, due to only five studies were included under
recessive model and allelic model. A significant associ-
ation between rs13181 and esophageal toxicity was iden-
tified by subgroup analysis by adverse effect (OR = 0.71,
95 % CI: 0.55-0.93, P = 0.01). No significant association
was found with acute skin toxicity (OR = 0.85, 95 % CI:
0.61-1.20, P = 0.36) and gastrointestinal toxicity (OR = 0.44,
95 % CI: 0.19-1.02, P = 0.06) (Table 2). Due to most in-
cluded studies of rs13181 (1417/1486 patients) evaluated
early adverse effect, the pooled result of early adverse effect
approximates with the result of overall toxicity (OR = 0.72,
95 % CI: 0.55-0.94, P = 0.02) (Table 2).
Heterogeneity and sensitivity analyses
The heterogeneities between studies of all analyses were
not significant. The pooled results present stable in the
sensitivity analysis (Fig. 4). The study Terrazzino 2012
possesses the greatest influence to the direction favors
wild type, while Zhang 2010 owns the greatest influence
to the direction of favors variant type. After omitting the
Fig. 1 Flow diagram of the literature review process
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Table 1 Baseline Characteristics of the Eligible Studies
Author, Year Country Ethnicity Disease Adverse Effect Assessment Criteria SNP MAF Sample Size EBRT Dose, Gy
Chang-Claude 2005 [40] Germany Caucasian Breast cancer Early effect: acute skin toxicity RTOG/EORTC≥ G2 rs13181, rs1799793 0.378,0.368 441 50-60
Chang-Claude 2009 [41] Germany Caucasian Breast cancer Late effect: telangiectasia RTOG/EORTC≥ G2 rs1799793 0.363 400 50-60
Duldulao 2013 [42] USA NR Rectal cancer Early effect: gastrointestinal and
abdominal toxicity
CTCAE v3.0≥ G3 rs13181 0.276 156 50.4-54
Fachal 2012 [43] Spain Caucasian Prostate cancer Early effect: gastrointestinal toxicity CTCAE v2.0≥ G2 rs1799793, rs1052555 0.342,0.328 698 70-76
Mangoni 2011 [44] Italy Caucasian Breast cancer Early effect: acute skin toxicity CTCAE v2.0≥ G2ca rs13181, rs1799793 NA 87 50-62.8
Raabe 2012 [45] Germany NR Breast cancer Early effect: acute skin toxicity RTOG/EORTC≥ G2 rs13181 0.646 82 50.4
Sakano 2010 [46] Japan Asian Bladder cancer Early effect: diarrhea CTCAE v3.0≥ G2 rs13181 NA 93 30.0-60.4
Terrazzino 2012 [47] Italy Caucasian Breast cancer Early effect: acute skin toxicity RTOG/EORTC≥ G2 rs13181 0.365 285 50-66
Yoon 2011 [48] USA Mixedb Esophageal cancer Early effect: esophageal toxicity
and myelosuppression
RTOG/EORTC≥ G3 rs13181, rs1799793, rs1052555 NA 60 46
Zhang 2010 [49] China NR Lung cancer Early effect: esophageal toxicity NR v2.0≥ G2 rs13181 0.286 213 50-70
Zschenker 2010 [50] Germany NR Breast cancer Late effect: fibrosis LENT/SOMA≥ G2 rs13181 0.551 69 54-55
Abbreviations: MAF minor allele frequency, RTOG the radiation therapy oncology group, EORTC European Organization for Research and Treatment of Cancer, EBRT external beam radiation therapy, CTCAE Common
Terminology Criteria for Adverse Events. NR not related. NA not available. SNP single nucleotide polymorphism











Fig. 2 Meta-analysis between ERCC2 polymorphisms and risk of radiotoxicity. A fixed-effects model was used. The square with the corresponding
horizontal line represents the OR and 95 % CI of each study. The area of the square reflects the weight of the study. The diamond represents the
pooled OR and 95 % CI. Power listed in the graph was calculated at the level of the corresponding OR
Table 2 Summary of meta-analysis results for the association between ERCC2 polymorphisms and radiotoxicity
Variable No. of cohorts Cases/Total OR [95 % CI]a Pz-test I
2 (%) Phet Power (%)
rs13181
Dominant model 9 342/1486 0.71 [0.55, 0.93] 0.01 0 0.59 79.2
Early adverse effect 8 325/1417 0.72 [0.55, 0.94] 0.02 0 0.49 73.8
Acute skin toxicity 4 219/895 0.85 [0.61, 1.20] 0.36 0 0.43 18.0
Acute esophageal toxicity 2 70/273 0.56 [0.32, 0.97] 0.04 0 0.49 54.6
Acute gastrointestinal toxicity 2 36/249 0.44 [0.19, 1.02] 0.06 0 0.87 52.7
Recessive model 5 286/1090 0.75 [0.50, 1.12] 0.16 43 0.14 27.4
Allelic model 5 286/1090 0.78 [0.64, 0.97] 0.02 27 0.24 68.5
rs1799793
Dominant model 5 256/1687 1.15 [0.86, 1.53] 0.34 0 0.41 16.9
Early adverse effect 4 130/1287 1.36 [0.96, 1.92] 0.09 0 0.75 35.2
Acute skin toxicity 2 84/529 1.48 [0.97, 2.26] 0.07 0 0.42 31.9
Recessive model 3 236/1540 0.67 [0.41, 1.08] 0.10 0 0.49 38.9
Allelic model 3 236/1540 0.99 [0.80, 1.23] 0.95 44 0.17 5.1
rs1052555
Dominant model 2 46/758 0.98 [0.53, 1.80] 0.95 0 0.74 5.1
PZ-test: P value of Z-Test for overall effect
Phet: P value of Chi
2 based Q-test for heterogeneity
aFixed-effect model used
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Fig. 3 Trial sequential analysis for rs13181 polymorphism on overall radiotoxicity. A diversity (D2) adjusted information size was calculated using
α = 0.05 (two-sided), β = 0.20 (power 80 %), and an anticipated relative risk reduction of 10 %. Diversity and control event proportion were set
basing the actual status of included data. The cumulative z-curve crossed the conventional boundary for significance, but did not cross any
adjusted boundary, leaving the meta-analysis inconclusive of an effect of RRR = 10 %
Fig. 4 Sensitivity analysis for rs13181 polymorphism
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study Zhang 2010, the pooled result was changed into
non-significance (OR = 0.78, 95 % CI: 0.58-1.04, P = 0.1).
Publication bias
The distribution of all the included studies of rs13181 in
Begg’s funnel plot was visually symmetrical (Additional
file 1: Figure S1), and the p-value of egger’s test was
0.891, which indicated that no obvious publication bias
exists in our meta-analysis of rs13181.
Discussion
Radiogenomics has entered the era of big data [31]. How-
ever, for the last decade candidate gene approach was pre-
dominant, and inconsistent results have been reported
due to most studies were underpowered with a relatively
small information size. Besides, some single SNP may con-
fer only slightly elevated risk of radiotoxicity, so it is diffi-
cult to identify this true effect without an enough sample
size. Hence, systematically summarizing the previous data
benefits of identifying a relatively small but significant
effect of relevant SNPs. In fact, meta-analysis has played
an important role in radiogenomics.
The present meta-analysis systematically summarized
the previous data of ERCC2 in radiogenomics. A signifi-
cant association between rs13181 and radiotoxicity was
identified by conventional meta-analysis. Our data re-
vealed that the major allele of rs13181 presents as a risk
allele, which means the minor allele confers a protect
effect against the appearance of radiotoxicity. However,
we should notice that this association was still borderline
(95 % CI: 0.55-0.93), and one study made the original sig-
nificance vanish in leave-one-out sensitivity analysis. In
addition, this conventional significance failed to get the
confirmation of TSA. We applied TSA with the intention
of drawing out more specific conclusions. TSA revealed
that the z-curve failed to further cross the α-spending
boundary after crossing the conventional boundary of
z = −1.96, which means the correlation between rs13181
polymorphism and radiotoxicity risk still need the con-
firmation of subsequent studies. To safely conclude an ef-
fect of OR = 0.71, additional 1400 patients were needed.
We performed subgroup analyses by adverse effect.
Radiation-induced adverse effects can be classified as early
or late effects according to the time before the manifest-
ation of relevant clinical symptoms. Most radiogenomics
studies reported early and late effects separately, and some
SNPs exert inconformity effect on early and late effects.
For instance, the pooled data of XRCC1 revealed that
Arg399Gln (rs25487) polymorphism significantly correlated
with an elevated risk of early radiotoxicity, while this SNP
was ruled out any clinical relevance with late radiotoxi-
city (Song YZ: The XRCC1 Arg399Gln Polymorphism and
Radiation-Induced Adverse Effects on Normal Tissue: Sys-
tematic Review with Meta-analysis and Trial Sequential
Analysis. Submitted). Meta-analysis of XRCC3 Thr241Met
(rs861539) polymorphism also reported a similar result,
that is a significant association with early radiotoxicity ra-
ther than late radiotoxicity [9]. In the present meta-
analysis, most studies evaluated early radiotoxicity, and
only one study involved late radiotoxicity, so it is note-
worthy that the pooled result of the present meta-analysis
mainly reflects the effect on early radiotoxicity. Within
early radiotoxicity, a significant association between
rs13181 polymorphism and acute esophageal toxicity was
also identified. However, this association should not be
over interpreted, due to only two studies were included in
this subgroup. The most evaluated radiotoxicity was acute
skin toxicity in the present meta-analysis, and four studies
evaluated this reaction following radiotherapy. The associ-
ation between rs13181 polymorphism and acute skin tox-
icity was not significant.
For interpreting the pooled result of a meta-analysis, ad-
equate evaluation on the heterogeneity between studies is
crucial (as was previously described in detail [9]). One of
the most important source of heterogeneity derived from
the heterogeneous treatment protocols among the in-
cluded studies. For instance, the radiotherapy parameters,
such as total dose, dose per fraction and irradiation vol-
ume, were not identical among the included studies. Some
treatment protocols of included studies involved chemo-
therapy as a component of multidisciplinary therapy, while
some were basing on radiotherapy alone. Toxicity evalu-
ation was another important source of heterogeneity. Both
the criteria applied and the division grade were not con-
sistent among included studies. Nevertheless, statistical
calculations did not identify obvious heterogeneity, we be-
lieved that the influence of these potential heterogeneity
factors were at an acceptable level.
Based on the radiogenomics studies throughout the last
decade, it is safe to conclude that no SNP alone possesses
the power to accurately predict the radio-sensitivity prior
radiotherapy [6, 31]. A study aiming to validate the as-
sociations previously reported between candidate SNPs
and radiotoxicity did not confirm any significant associ-
ation [32]. To date, six genome-wide association studies
(GWASs) have been published on radiogenomics [33–38].
The SNPs which were identified with a genome-wide sig-
nificance were not located in the region supposed by candi-
date gene association studies. However, statically significant
conclusions were constantly reported by meta-analyses of
candidate gene association studies. Through combining in-
formation of all the relevant studies, more statistical power
was acquired [39]. Evidence of meta-analysis has revealed
that XRCC1 rs25487, XRCC3 rs861539, ATM rs1801516
and ERCC2 rs13181 polymorphisms significantly associated
with early radiotoxicity, though the effect size was relatively
small [8, 9]. While an individual candidate SNP was not ex-
pected to confer a large effect on radiotoxicity. Instead,
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composing a synthesized risk model is the major modality
how the relevant SNPs play a role on the prediction of
radio-sensitivity. Despite a relatively small effect (with odds
radios of 1.2 to 1.5) exerted on radiotoxicity by individual
SNP, an enough prediction power can be accrued by involv-
ing multiple such SNPs.
Conclusions
Although the minor allele of rs13181 polymorphism was
identified with a protect effect against radiotoxicity, it is
noteworthy that the correlation was borderline, and one
included study made the overall meta-analysis loss the stat-
istical significance in leave-one-out sensitivity analysis. In
addition, this significant association identified by traditional
meta-analysis failed to get the conformation of TSA. More
studies with additional 1400 patients were needed to draw
the firm conclusion at the level of OR = 0.71.
Additional file
Additional file 1: Figure S1. Begg’s funnel plot for the meta-analysis of
rs13181. Supplementary material: The specific search strategy. (PDF 305 kb)
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